Conference Description:

Understanding the patient's perspective is essential to driving the success of clinical trials, accelerating regulatory approvals, and enhancing the patient experience throughout their healthcare journey. Yet, amidst a challenging funding environment, empowered patients rightfully demanding greater involvement in treatment decisions, and regulatory bodies requiring transparent reporting of patient engagement activities, it has become more critical than ever to establish quantitative measures for assessing the impact of these initiatives.

Despite this, a standardized approach to measuring the success of patient engagement strategies has yet to emerge. While patient affairs professionals recognize that meaningful engagement leads to treatments that better align with the needs of patients, the pharmaceutical industry has struggled to clearly demonstrate the value of patient engagement to all stakeholders. To ensure patient engagement remains a cornerstone of healthcare innovation, the industry must adopt a unified framework for measuring its value and impact.

The 2nd Measuring Patient Engagement Summit 2025 aims to address this critical challenge. This transformative event brings together leading experts in Patient Engagement, Advocacy, Affairs, Experience, Insights, Marketing, and beyond to share actionable case studies on how to quantitatively and objectively measure patient engagement. By standardizing these approaches, participants will gain the tools they need to demonstrate the value of their initiatives to both internal and external stakeholders, ensuring patient engagement remains a strategic priority across the product development lifecycle and therapeutic landscapes.

Join us in driving the future of patient-centered innovation - because when we measure what matters, we create a healthcare system that truly works for everyone.

URL:
Tickets: https://go.evvnt.com/2824153-1?pid=154
Time: 9:00 AM - 5:00 PM

Prices:
Drug Developer - Conference + 2 Workshops: USD 4297.00,
Drug Developer - Conference + 1 Workshop: USD 3648.00,
Drug Developer - Conference Only: USD 2999.00,
Academic Pricing - Conference + 2 Workshops: USD 3697.00,
Academic Pricing - Conference + 1 Workshop: USD 3148.00,
Academic Pricing - Conference Only: USD 2599.00,
Solution Provider Pricing - Conference + 2 Workshops: USD 5197.00,
Solution Provider Pricing - Conference + 1 Workshop: USD 4448.00,
Solution Provider Pricing - Conference Only: USD 3699.00

Speakers: Adrienne Gaggi, Director of Innovative Patient Recruitment, AstraZeneca, Alan Ryan, Senior Director, Patient Advocacy, Ardelyx, Alexandra Moutet, Global Head of Patient Engagement, UCB, Amy Fisher, Senior Director and Head of Patient Advocacy, Spark Therapeutics, Barbara Penninckx, Global Patient Engagement and Advocacy Lead, UCB, Camille Wilhelmi, Associate Director, Patient Engagement, Novartis, Catherine Jackson, Senior Director, Patient Engagement and Advocacy, Mallinckrodt Pharmaceuticals, Emma Sutcliffe, Chief Patient Officer, ISPEP, Giulia Ghibellini, Patient Focused Medical Engagement, Lead Global Medical Affairs, Teva Pharmaceuticals, Hayley Chapman, Senior Director - Program, PFMD, Josee Pelletier, Senior Director, Research and Drug Development, Global Patient Advocacy Corporate Affairs, BMS, Karin Mitchell, Director, Advocacy and Patient Reimbursement Services, Omeros Corporation, Kelli Wright, Director, Patient Advocacy, Day One Biopharmaceuticals, Laura Russo, Patient Affairs Lead, Pfizer, Lori Ann, Correia Patient Advocacy Consultant, Tenaya Therapeutics, Maria Marano, Associate Program Director, PFMD, Paula Hines, Senior Director, Global Regulatory Affairs, Immunology Innovative Medicines, Teva Pharmaceuticals, Sharl Azar, Medical Director, Massachusetts General Hopsital, Suepattra May-Slater, Senior Director, Patient Advocacy, Stemline Therapeutics, Tab Cooney, Medical Director, Day One Biopharmaceuticals, Teresa Cronin, Vice President - Corporate Communications and Patient Advocacy, Eisai, Tiffany Patrick, Senior Vice President - Patient and Professional Advocacy, Amicus Therapeutics